Literature DB >> 12427233

Analysis of the Arg345Trp disease-associated allele of the EFEMP1 gene in individuals with early onset drusen or familial age-related macular degeneration.

Robyn H Guymer1, Robyn McNeil, Melinda Cain, Belinda Tomlin, Penelope J Allen, Chi Luu Dip, Paul N Baird.   

Abstract

BACKGROUND: A single base change within the EFEMP1 gene has been associated with malattia leventinese and Doyne honeycomb retinal dystrophy, two dominantly inherited macular diseases with early onset drusen. The aim of this study was to determine whether the same disease allele was also associated with other forms of early onset drusen or familial cases of age-related macular degeneration.
METHODS: Thirteen index cases of early onset drusen together with 15 other family members were examined. In addition, 54 familial cases of age-related macular degeneration were examined. Blood was taken for DNA analysis and screened for the Arg345Trp disease-associated allele of the EFEMP1 gene. Twenty-four cases of malattia leventinese or Doyne honeycomb retinal dystrophy were also screened as positive controls. Another 150 ethnicity- and age-matched individuals acted as controls.
RESULTS: The Arg345Trp disease-associated allele in the EFEMP1 gene was confirmed in individuals with malattia leventinese and Doyne honeycomb retinal dystrophy. However, involvement of this allele was not evident in either early onset drusen or familial age-related macular degeneration.
CONCLUSIONS: The Arg345Trp disease-associated allele of the EFEMP1 gene does not appear to be associated with cases of early onset drusen that fall outside the diagnosis of malattia leventinese or Doyne honeycomb retinal dystrophy, nor does it appear to play a role in familial age-related macular degeneration. These findings do not exclude the involvement of other alleles of the EFEMP1 gene in either phenotype. The genetic mechanisms involved in the heterogeneous group of early onset drusen remain to be elucidated but should lead to insights into the genetic causes of macular diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427233     DOI: 10.1046/j.1442-9071.2002.00572.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  6 in total

1.  Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration.

Authors:  Sudha K Iyengar; Danhong Song; Barbara E K Klein; Ronald Klein; James H Schick; Jennifer Humphrey; Christopher Millard; Rachel Liptak; Karlie Russo; Gyungah Jun; Kristine E Lee; Bonnie Fijal; Robert C Elston
Journal:  Am J Hum Genet       Date:  2003-12-19       Impact factor: 11.025

Review 2.  Genetic factors of age-related macular degeneration.

Authors:  Jingsheng Tuo; Christine M Bojanowski; Chi-Chao Chan
Journal:  Prog Retin Eye Res       Date:  2004-03       Impact factor: 21.198

Review 3.  Genetics of age-related macular degeneration: current concepts, future directions.

Authors:  Margaret M Deangelis; Alexandra C Silveira; Elizabeth A Carr; Ivana K Kim
Journal:  Semin Ophthalmol       Date:  2011-05       Impact factor: 1.975

4.  A novel haplotype with the R345W mutation in the EFEMP1 gene associated with autosomal dominant drusen in a Japanese family.

Authors:  Tomokazu Takeuchi; Takaaki Hayashi; Matthew Bedell; Kang Zhang; Hisashi Yamada; Hiroshi Tsuneoka
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

5.  Genetic variations strongly influence phenotypic outcome in the mouse retina.

Authors:  Austin S Jelcick; Yang Yuan; Barrett D Leehy; Lakeisha C Cox; Alexandra C Silveira; Fang Qiu; Sarah Schenk; Andrew J Sachs; Margaux A Morrison; Arne M Nystuen; Margaret M DeAngelis; Neena B Haider
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

6.  Fibulin-3 knockout mice demonstrate corneal dysfunction but maintain normal retinal integrity.

Authors:  Steffi Daniel; Marian Renwick; Viet Q Chau; Shyamtanu Datta; Prabhavathi Maddineni; Gulab Zode; Emma M Wade; Stephen P Robertson; W Matthew Petroll; John D Hulleman
Journal:  J Mol Med (Berl)       Date:  2020-09-22       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.